Fig. 5

Calnexin levels correlate with poor clinical outcome in rectal cancer patients treated in the neoadjuvant setting. The calnexin level was significantly increased in rectal cancer patients who received neo-adjuvant radiochemotherapy (50.4 Gy + 5FU) and had a poor clinical outcome (RCPath B & C) compared with patients who received neo-adjuvant radiochemotherapy with good clinical outcome (RCPath A; *p = 0.0061; Mann–Whitney U Test; Bonferroni corrected significance level α = 0.0125)